Tumor Treatment

Tumor Treatment

LiquidHALLMARK®


Our flagship blood test that simultaneously detects cancer-causing gene mutations and viruses in multiple cancers to improve cancer diagnosis and treatment selection.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Multiple Cancers Blood 10 Days

LiquidHALLMARK® is the world’s first sequencing test that detects cancer-causing gene mutations and viruses from circulating tumor DNA in blood. The test detects clinically relevant mutations in 14 types of cancers including breast, colon, lung, liver, and nasopharyngeal cancers, among others. It covers microsatellite instability (MSI) and cancer-associated viruses such as Epstein-Barr virus (EBV) and Hepatitis B virus (HBV). The test is based on Lucence’s core molecular watermarking technology AmpliMARK™ for accurate and ultra-deep sequencing results.

Benefits:

  • Non-invasive. Requires only one draw of blood
  • Provide actionable clinical information
  • > 99% sensitivity and specificity
  • Customized to detect Asian cancers

Recommended For:

  • Patients with advanced or late stage cancers
  • Patients who have tested negative for single gene mutations and require more comprehensive tumor profiling.
  • Patients with cancers of unknown primary origin
  • Patients with inadequate amount of tissue or unobtainable tissue for tissue biopsy
  • Patients who may prefer non-invasive testing or are not suitable for invasive surgical procedure
Target List
Genes*
ABL1 CDKN2A FLT3 IDH2 MED12 PIK3CA
AKT1 CTNNB1 GATA3 JAK1 MET# PTEN
ALK# EGFR GNA11 JAK2 MTOR RAF1
AR ERBB2 (HER2)# GNAQ JAK3 MYC# SMAD4^
ATM ESR1 GNAS KIT NFE2L2 STK11
BRAF FBXW7 HNF1A KRAS NOTCH1 TERT promoter
CCND1# FGFR2 HRAS MAPK1 (ERK2) NRAS TP53^
CDH1 FGFR3 IDH1 MAP2K1 (MEK1) PDGFRA VHL
Fusions
ALK RET ROS1
MSI
BAT25 BAT26 NR21 NR24 NR27 MONO27
Viruses
EBV HBV

* Targeted regions selected to maximize detection of known hotspot mutations. List available on request.
Includes sequencing of EGFR mutations in exons 18-21 such as T790M and C797S.
# Detection of genetic variants and amplification.
^ Full coverage.

LiquidMARK


LiquidMARK™ is a subset of cancer-specific blood tests under LiquidHALLMARK® for 14 types of cancers that include breast, colon, and lung cancers.

Gene List
Tests Targets Turnaround Time
LiquidMARK™ Breast Genes*: AKT1, CDH1, ERBB2 (HER2)#, ESR1, GATA3, MYC#, PIK3CA, PTEN, TP53^

MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27
10 days
LiquidMARK™ Colon Genes*: APCBRAF, ERBB2 (HER2)#, FBXW7, JAK1, KRAS, MYC#, NRAS, PIK3CA, RAF1, TP53^

MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27
10 days
LiquidMARK™ Lung Genes*: ALK#, BRAF, EGFR, ERBB2 (HER2)#, KRAS, MET#, NRAS, PIK3CA, STK11, TP53^

Fusions: ALK, RET, ROS1

MSI: BAT25, BAT26, NR21, NR24, NR27, MONO27

10 days

Click here to view the gene list of all our LiquidMARK™ tests.

* Targeted regions selected to maximize detection of known hotspot mutations. List available on request.
Includes sequencing of EGFR mutations in exons 18-21 such as T790M and C797S.
# Detection of genetic variants and amplification.
^ Full coverage.

References:
1. Choudhury, Y. et al. Journal of Clinical Oncology, 36, 2018 (suppl; abstr e24107)
2. Vo, J. H. et al., Scientific Reports, 6:13 (2016)
3. Tan, M.H. and Vo, J. H. Patent Cooperation Treaty Application No. PCT/SG2016/050611 (2016)
4. Choudhury, Y., Chen, H. and Tan, M. H. Singapore Patent Application No. 10201805450Y (2018)

Guideline88


World’s first blood test that detects 8 guideline-recommended genes in lung cancer for effective treatment.

Cancer Type
···
Sample Type
···
Turnaround Time
···
Lung Blood 8 Days

Molecular testing for 8 genes is recommended by international treatment guidelines for patients with advanced non-small cell lung cancer because effective treatment is available. Patients with specific genetic markers have been shown to benefit from improved quality of life and progression-free survival after receiving targeted therapy. The markers include microsatellite instability (MSI) which predicts patient response to immunotherapy. The test is based on Lucence’s core molecular watermarking technology AmpliMARK™.

Benefits:

  • Detects genetic mutations with FDA-approved targeted therapy.
  • > 99% sensitivity and specificity.
  • Non-invasive. Requires one draw of blood.

Recommended For:

  • Patients with advanced non-small cell lung cancer.
Target List
Genes
EGFR ALK RET ROS1 BRAF MET ERBB2
(HER2)
KRAS
MSI
BAT25 BAT26 NR21 NR24 NR27 MONO27
The test is based on treatment guidelines from:
  • • National Comprehensive Cancer Network (NCCN)
  • • College of American Pathologists (CAP)
  • • International Association for the Study of Lung Cancer (IASLC)
  • • Association for Molecular Pathology (AMP)

References:
1. David S. E. et al, Journal of the National Comprehensive Cancer Network, 2018 16(6):807-821.
2. Lindeman, NI. et al, Journal of Molecular Diagnostics, 2018 (20) 129-159.

LiquidSCREEN™ & LiquidTRACK


Blood tests that detect and track specific cancer mutations in the tumor for cancer diagnosis and treatment.

 

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Lung Blood and
Cerebrospinal Fluid
2 Days

LiquidSCREEN™ and LiquidTRACK™ detect specific cancer mutations from circulating tumor DNA in blood. The tests help physicians select targeted therapies and monitor treatment response based on the cancer-driving mutation. Based on our proprietary technology, the tests detect the quantitative level of mutation present in blood, allowing for more accurate disease monitoring. The technology has been clinically validated in a multicentre Singapore study.

LiquidSCREEN™

  • Patient: Has not done liquid biopsy before
  • Objective: To detect cancer driving mutation
    for treatment selection LiquidSCREEN™

LiquidTRACK™

  • Patient: Has done LiquidSCREEN™ and identified
    the sensitizing and resistance mutation
  • Objective: To monitor and detect resistance to
    treatment

Benefits:

  • Simple and non-invasive. One draw is all it takes
  • Test results back in 2 working days for rapid decision making
  • Ultrasensitive with detection limits of up to 0.01%

Recommended For:

  • Patients with advanced or late stage cancers
  • Patients with inadequate amount of tissue or unobtainable tissue for tissue biopsy
  • Patients who may prefer non-invasive testing or are not suitable for invasive surgical procedure
Gene List
Tests Genes Sequenced Turnaround Time
LiquidSCREEN™ Lung Exon 18: G719A, G719C, G719S
Exon 19: delE746-A750, delL747-P753insS, delL747-A750insP, delL747-T751
Exon 20: T790M
Exon 21: L858R, L861Q
2 days
LiquidTRACK™ Lung EGFR : Selected patient-matched sensitizing mutations such as T790M and C797S 2 days

Bundled EXPRESS Service

Order both LiquidSCREEN™ Lung + LiquidMARK™ Lung
to get faster turnaround time

LiquidSCREEN™ Lung

1 day (instead of 2 days)

LiquidMARK™ Lung

10 days


References:
1. Luo, J. et al. A Systematic Review and Meta-Analysis, Science Reports, 4: 6269, 2014.
2. Kobayashi, S. et al. The New English Journal of Medicine, 352(8):786-792, 2005.
3. Janne, PA. et al. The New English Journal of Medicine, 372(18), 1689-1699, 2015.
4. Shi, J. et al. Annals of Oncology, Volume 28, Issue suppl_5, 2017.

LumiBRCA™ & LumiTHERA


Companion diagnostic tests that detect specific genetic mutations in breast and ovarian cancers for targeted treatment.

Cancer
Type
···
Sample
Type
···
Turnaround
Time
···
Breast and
Ovarian Cancers
Blood 2-3 Weeks

LumiBRCA™ and LumiTHERA™ are blood tests that detects BRCA and other genetic mutations associated with breast and ovarian cancers for targeted treatment.

In addition to our specialized sequencing, our tests also include multiplex ligation-dependent probe amplification (MLPA) screening. MLPA allows us to detect large genomic rearrangements in BRCA genes, which contributes 11-36% of all BRCA genetic variants. The tests will help physicians to decide whether a patient is suitable for an FDA-approved targeted therapy called PARP inhibitor and immunotherapy for treatment of breast and ovarian cancers.

What is the difference between
LumiBRCA™ and LumiTHERA™?

LumiBRCA™ tests for mutations involving the BRCA genes together with mutations arising from large genomic rearrangements to check if the patient’s tumor is suitable for PARP inhibitor therapy.

LumiTHERA™ is an expanded version of LumiBRCA™ that includes the genes involved with the mismatch repair function to check if the patient’s tumor is suitable for both PARP inhibitor therapy and immunotherapy.

Benefits:

  • Non-Invasive. One draw of blood for diagnosis
  • Complete coverage of entire coding sequences of BRCA1
    and BRCA2
  • Close to 100% sensitivity and specificity
  • Cancer genetics counsellor at Lucence available for
    discussion with the ordering physician for optimal
    diagnosis and management

Recommended For:

  • Patients diagnosed with breast and/or ovarian cancers
GENES
LumiBRCA™
LumiTHERA™
ATM
BRCA1
BRCA2
BRIP1
CHEK2
EPCAM
MLH1
MSH2
MSH6
MUTYH
NBN
PALB2
PMS2
PTEN
RAD51C
RAD51D

References:
1. FDA grants accelerated approval to new treatment for advanced ovarian cancer (2016)
2. European Medicines Agency (2015)
3. Alsop, K. et al. J Clin Oncol. 30, 2654-2663, 2012
4. Moller, P. et al. Eur J Cancer, 43, 1713-1717, 2007 5. Zhang, S. et al. Gynecol. Oncol. 121, 353-357, 2011
5. Casilli et al. J Med Genet, 43(9):e49, 2006
6. Eccles, D. M. et al. Adv. Ther. 33, 129-150, 2016
7. Sluiter & Rensburg, Breast Cancer Res Treat. 125(2):325-49, 2011
8. AstraZeneca Press Release: Lynparza meets primary endpoint in Phase III trial in BRCA-mutated metastatic breast cancer (2017)

HemeMARK


Obtain in-depth genomic profile of the patient’s haematological malignancy that covers a range of myeloid and lymphoid neoplasms.

Cancer Type
···
Sample Type
···
Turnaround Time
···
Haematological Malignancies Blood and Bone Marrow 10 Days

HemeMARK™ is a next-generation sequencing (NGS) based assay that detects cancer-related gene mutations from blood or bone marrow for diagnosis, treatment selection, and monitoring. This NGS test detects clinically relevant mutations in various types of hematological malignancies including leukemia, lymphoma, and myeloma. This test is based on Lucence’s core molecular watermarking technology AmpliMARK™.

Target List
Genes
ABL1  CCND3 EZH2 IKZF1 NOTCH1 TET2
ASXL1 CD79B FBXW7 JAK2 NPM1 TP53
ATM CDKN2A FGFR3 JAK3 NRAS U2AF1
BRAF CDKN2B FLT3 KIT RUNX1  
BTK CEBPA HRAS KRAS SETBP1  
CALR CREBBP ID3 MPL SF3B1  
CBL CSF3R IDH1 MYC SRSF2  
CCND1 DNMT3A IDH2 MYD88 TCF3  
Fusion
BCR/ABL1
MSI
BAT25 BAT26 NR21 NR24 NR27 MONO27

Tissue500


A comprehensive test panel that analyses more than 500 genes

Cancer Type
···
Sample Type
···
Turnaround Time
···
All solid tumors FFPE Tumor Tissue 4 Weeks

Tissue500™ is a comprehensive genomic profiling test that detects clinically-relevant genomic alterations in more than 500 genes to identify suitable target therapies for personalized medicine. It is able to detect multiple classes of genomic alterations and provide the status of microsatellite instability and tumor mutational burden. Broad molecular profiling picks up unanticipated and rare driver mutations, defining individual tumors to inform physicians of unique genomic signatures for personalized medicine.

Click here for the full Tissue500™ gene list.

Benefits:

  • Analyses more than 500 genes for SNV and indel detection and 55 genes for fusion and splice variants detection
  • Matches patients to available FDA-approved targeted therapy and immunotherapy, or clinical trials to tailor cancer treatments
  • Provides comprehensive genomic analysis and biomarker status from limited tissue in one test
  • Covers all NCCN guideline-recommended genes in solid tumors, emerging biomarkers, and genes involved in over 1600 clinical trials

Recommended For:

  • Newly diagnosed patients
  • Recurrent and metastatic disease
  • Patients who are not responding well to current standard-of-care treatments

TissueHRD


A companion diagnostic test that detects mutations in HRD genes

Cancer Type
···
Sample Type
···
Turnaround Time
···
Ovarian, Breast, Prostate and Pancreas FFPE Tumor Tissue 4 Weeks

TissueHRD™ is a companion diagnostic test that detects pathogenic mutations in genes implicated in the homologous recombination pathway to determine the homologous recombination –deficiency (HRD) status of a tumor. HRD has been associated with improved outcomes using DNA-damaging therapies. Knowing the HRD status of a tumor can guide treatment selection of FDA-approved PARP inhibitors and other DNA-damaging agents.


Target List
Genes
ARID1A  BARD1 CHEK1  FANCD2  FANCL  RAD50 
ATM BLM CHEK2  FANCE  MRE11A  RAD51 
ATRX BRCA1 FANCA  FANCF  NBN  RAD51B 
BAP1 BRCA2 FANCC  FANCG  PALB2   

Recommended For:

  • Comprehensive analysis of genes associated with HRD, including BRCA1 and BRCA2
  • Identifies patients who may benefit from PARPi treatment

Recommended For:

  • Patients with ovarian, breast, prostate, and pancreatic cancers

Tissue PD-L1 Triplex


Match patient's suitability across 3 immunotherapy drugs in 1 test.

Cancer Type
···
Sample Type
···
Turnaround Time
···
All Cancer Types FFPE Tumor Tissue 3 Weeks

The world’s first immunohistochemistry (IHC) tissue test that concurrently determines the expression of 3 clinically relevant tumor programmed death-ligand 1 (PD-L1) clones in 1 tissue sample.

Using quantitative multiplex fluorescence-IHC, Tissue PD-L1 Triplex™ determines the expression of PD-L1 clones SP142, SP263 and 22C3 in tumor cells and tumor-infiltrating immune cells which in turn, provides insights to the potential response of the patient towards immunotherapy.

IMMUNOTHERAPY MATCH
Atezolizumab Durvalumab Pembrolizumab Nivolumab
Non-Small Cell Lung Cancer (NSCLC) SP142 ≥ 50% TPS or ≥ 10% IC associated with enhanced overall survival SP263 ≥ 1% TPS – Post chemoradiation therapy (CRT) SP263 ≥50% TPS – First Line

SP263 ≥1% TPS – Second Line

 

22C3 ≥50% TPS – First Line

22C3 ≥1% TPS – Second Line

SP263 ≥1%, ≥5% and ≥10% TPS – Second Line
Urothelial Carcinoma SP142 ≥ 5% IC SP263 ≥25% TPS – Second Line

SP263 ≥ 25% IC – Second Line

Triple Negative Breast Cancer (TNBC) SP142 ≥ 1% IC


Need Help?